FR2986230B1 - Nouveaux composes et compositions utilises comme anticancereux - Google Patents

Nouveaux composes et compositions utilises comme anticancereux

Info

Publication number
FR2986230B1
FR2986230B1 FR1250863A FR1250863A FR2986230B1 FR 2986230 B1 FR2986230 B1 FR 2986230B1 FR 1250863 A FR1250863 A FR 1250863A FR 1250863 A FR1250863 A FR 1250863A FR 2986230 B1 FR2986230 B1 FR 2986230B1
Authority
FR
France
Prior art keywords
anticancer
compositions
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1250863A
Other languages
English (en)
Other versions
FR2986230A1 (fr
Inventor
Eric Raymond
Sandrine Faivre
Laurent Desaubry
Nigel Ribeiro
Christophe Salome
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Universite Paris Diderot Paris 7
Universite de Strasbourg
Original Assignee
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Universite Paris Diderot Paris 7
Universite de Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Assistance Publique Hopitaux de Paris APHP, Universite Paris Diderot Paris 7, Universite de Strasbourg filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR1250863A priority Critical patent/FR2986230B1/fr
Priority to PCT/FR2013/050186 priority patent/WO2013114040A1/fr
Publication of FR2986230A1 publication Critical patent/FR2986230A1/fr
Application granted granted Critical
Publication of FR2986230B1 publication Critical patent/FR2986230B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR1250863A 2012-01-30 2012-01-30 Nouveaux composes et compositions utilises comme anticancereux Expired - Fee Related FR2986230B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1250863A FR2986230B1 (fr) 2012-01-30 2012-01-30 Nouveaux composes et compositions utilises comme anticancereux
PCT/FR2013/050186 WO2013114040A1 (fr) 2012-01-30 2013-01-30 Nouveaux composes et compositions utilises comme anticancereux

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1250863A FR2986230B1 (fr) 2012-01-30 2012-01-30 Nouveaux composes et compositions utilises comme anticancereux

Publications (2)

Publication Number Publication Date
FR2986230A1 FR2986230A1 (fr) 2013-08-02
FR2986230B1 true FR2986230B1 (fr) 2014-03-07

Family

ID=47754782

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1250863A Expired - Fee Related FR2986230B1 (fr) 2012-01-30 2012-01-30 Nouveaux composes et compositions utilises comme anticancereux

Country Status (2)

Country Link
FR (1) FR2986230B1 (fr)
WO (1) WO2013114040A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104710394B (zh) * 2015-03-12 2017-09-19 中国药科大学 香豆雌酚开环类似物及其医药用途
EP3694528A4 (fr) * 2017-10-13 2021-07-28 The Regents of the University of California Modulateurs de mtorc1
CN113234044B (zh) * 2021-01-11 2022-10-21 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种杂萜结构化合物及其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway

Also Published As

Publication number Publication date
FR2986230A1 (fr) 2013-08-02
WO2013114040A1 (fr) 2013-08-08

Similar Documents

Publication Publication Date Title
IL265327A (en) xten duo preparations and methods for their production
BR112015002651A2 (pt) composições cosméticas
DK2931970T4 (da) Cellulose-afledte sammensætninger
DK2640893T4 (da) Sammensætninger
DK3072510T3 (da) Omega-3-fedtsyreestersammensætninger
DK3590358T3 (da) Næringsmiddelsammensætning
BR112013017183A2 (pt) composições de bepostatina
DK2882433T3 (da) Antimikrobielle sammensætninger omfattende glycerylnitrater
CO6930368A2 (es) Composiciones de yodo-povidona estable
BR112013014204A2 (pt) composições de sucops espumantes
HK1205947A1 (en) Uses of casein compositions
DK2822967T3 (da) Compositions comprising secretory - like immunoglobulins
BR112013022478A2 (pt) composições de alumínio-carbono
BR112013012240A2 (pt) Composições de suplemento alimentar
SG11201405575YA (en) Modified polymer compositions
BR112014009636A2 (pt) composição dietética destinada à prevenção do risco cardiometabólico
BR112014020677A2 (pt) composições de farinha de milho e métodos de produção
HK1205954A1 (en) Companion cosmetic compositions
EP2867199A4 (fr) Compositions stables de fésotérodine
BR112013031545A2 (pt) composições cosméticas
FR2986230B1 (fr) Nouveaux composes et compositions utilises comme anticancereux
CR20140186A (es) Composiciones mejoradas
DK2934593T3 (da) Cabazitaxel composition
DK2811828T3 (da) Adjuvanssammensætninger
BR112013031357A2 (pt) composições cosméticas

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 4

ST Notification of lapse

Effective date: 20160930